From metastatic disease to no evidence of disease after conversion liver surgery in advanced gastric cancer with liver metastases: A case report.
- 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Abstract
Stage IV gastric cancer with liver metastases has a poor prognosis. Conversion surgery may enable long-term disease control in selected patients, but pathological complete response is rare and is usually defined only for surgically resected specimens. Here, a 54-year-old female with initially unresectable, HER2-negative, pMMR-by-IHC, EBER-positive gastric cancer and synchronous liver metastases received first-line XELOX plus tislelizumab for 4 cycles. Because of suspected oxaliplatin hypersensitivity, treatment was changed to cisplatin plus capecitabine plus tislelizumab for 3 cycles. After subsequent suspected platinum hypersensitivity, treatment was changed to capecitabine plus tislelizumab for 7 cycles. After 14 cycles, repeat endoscopic biopsy showed no tumor cells. Imaging showed significant regression of liver lesions. After multidisciplinary discussion, the patient underwent conversion liver surgery comprising resection of selected liver lesions and radiofrequency ablation of other liver lesions. R0 status was confirmed only for the resected liver specimens; ablated lesions had no pathological specimen. Histopathological examination of the resected liver specimens showed no residual viable tumor cells, consistent with pathological complete response in the resected liver lesions. The gastric primary was assessed as clinical complete response by endoscopy and biopsy. At last follow-up 1 month after surgery, imaging showed no evidence of disease; long-term outcome remains unknown. This case illustrates that selected patients with advanced gastric cancer and liver metastases may achieve a strong response to tislelizumab-based immunochemotherapy and liver-directed conversion treatment. However, the long-term benefit, the role of omitting gastrectomy, and the significance of FAPI/FDG discordance remain uncertain.
Related
- A Contemporary Review of Resectability and Treatment Strategies for Colorectal Liver Metastases: Part 2-Advanced Surgical Techniques, Conversion Strategies, and the Expanding Boundaries of Treatment.
- Molecular, histopathological, and clinical risk factors for overall metastatic disease and brain metastases in surgically resected stage I-III lung cancer.
- Sequential surgery after conversion therapy for advanced hepatocellular carcinoma: Evidence, controversies, and perspectives
- Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study
- From Evidence to Implementation: FIB-4-Based Risk Stratification for Advanced Liver Disease in Saudi Primary Care
BibTeX
@article{chen2026from,
title = {{From metastatic disease to no evidence of disease after conversion liver surgery in advanced gastric cancer with liver metastases: A case report.}},
author = {Dong Chen and Hanyu Wang and Lin Xu},
journal = {Human vaccines \& immunotherapeutics},
year = {2026},
month = oct,
doi = {10.1080/21645515.2026.2750040},
url = {https://europepmc.org/article/MED/42911554},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - From metastatic disease to no evidence of disease after conversion liver surgery in advanced gastric cancer with liver metastases: A case report.
AU - Dong Chen
AU - Hanyu Wang
AU - Lin Xu
PY - 2026
DA - 2026/10/22
JO - Human vaccines & immunotherapeutics
DO - 10.1080/21645515.2026.2750040
UR - https://europepmc.org/article/MED/42911554
AB - Stage IV gastric cancer with liver metastases has a poor prognosis. Conversion surgery may enable long-term disease control in selected patients, but pathological complete response is rare and is usually defined only for surgically resected specimens. Here, a 54-year-old female with initially unresectable, HER2-negative, pMMR-by-IHC, EBER-positive gastric cancer and synchronous liver metastases received first-line XELOX plus tislelizumab for 4 cycles. Because of suspected oxaliplatin hypersensitivity, treatment was changed to cisplatin plus capecitabine plus tislelizumab for 3 cycles. After subsequent suspected platinum hypersensitivity, treatment was changed to capecitabine plus tislelizumab for 7 cycles. After 14 cycles, repeat endoscopic biopsy showed no tumor cells. Imaging showed significant regression of liver lesions. After multidisciplinary discussion, the patient underwent conversion liver surgery comprising resection of selected liver lesions and radiofrequency ablation of other liver lesions. R0 status was confirmed only for the resected liver specimens; ablated lesions had no pathological specimen. Histopathological examination of the resected liver specimens showed no residual viable tumor cells, consistent with pathological complete response in the resected liver lesions. The gastric primary was assessed as clinical complete response by endoscopy and biopsy. At last follow-up 1 month after surgery, imaging showed no evidence of disease; long-term outcome remains unknown. This case illustrates that selected patients with advanced gastric cancer and liver metastases may achieve a strong response to tislelizumab-based immunochemotherapy and liver-directed conversion treatment. However, the long-term benefit, the role of omitting gastrectomy, and the significance of FAPI/FDG discordance remain uncertain.
SN - 2164-5515
SN - 2164-554X
ER -